Results 61 to 70 of about 5,991,558 (223)

Lupus-Like Syndrome Caused by 5-Aminosalicylic Acid in Patients with Inflammatory Bowel Disease

Canadian Journal of Gastroenterology, 1999
BACKGROUND: Although 5-aminosalicylic acid (5-ASA) preparations used to treat inflammatory bowel disease are reported to have fewer side effects than sulphasalazine, increased clinical use of these compounds has resulted in increased reports of ...
Andrew W Kirkpatrick, Arthur A Bookman, Flavio Habal   +2 more
doaj   +1 more source

Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes

Frontiers in Microbiology, 2017
Campylobacter concisus is a bacterium that is associated with inflammatory bowel disease (IBD). Immunosuppressive drugs including azathioprine (AZA) and mercaptopurine (MP), and anti-inflammatory drug such as 5-aminosalicylic acid (5-ASA) are commonly ...
Fang Liu, Rena Ma, S. Riordan, M. Grimm, Lu Liu, Yiming Wang, Li Zhang   +6 more
semanticscholar   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis [PDF]

Intestinal Research, 2018
Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been demonstrated, a few patients paradoxically develop a severe
Jun Miyoshi, Katsuyoshi Matsuoka, Atsushi Yoshida, Makoto Naganuma, Tadakazu Hisamatsu, Tomoharu Yajima, Nagamu Inoue, Susumu Okamoto, Yasushi Iwao, Haruhiko Ogata, Fumiaki Ueno, Toshifumi Hibi, Takanori Kanai   +12 more
doaj   +1 more source

Deep learning‐assisted design of nanozyme for immune regulation

Journal of Intelligent Medicine, Volume 3, Issue 3, Page 250-276, September 2026.
Overview of nanozyme‐based strategies for inflammatory bowel disease therapy, featuring metal‐based and non‐metallic nanozymes classified by structure, alongside multifunctional and engineered probiotic‐based nanozymes classified by function. Abstract Inflammatory bowel disease (IBD), with rising global incidence and disease burden, is a multifactorial
Ke Chen, Si Sun, Shaofang Zhang, Huanhuan Qiao   +3 more
wiley   +1 more source

The Mycobacterium tuberculosis Rv0132c Gene Product Mtb‐FGD2 Can Act as an F420‐Dependent Glucose Dehydrogenase

Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 9, Page 1610-1627, September 2026.
ABSTRACT The role of the cell envelope‐associated Rv0132c/FGD2 from Mycobacterium tuberculosis has long been a subject of debate. Importantly, FGD2 is found only in pathogenic mycobacteria, making it a potential drug target. While some suggest it functions as a glucose‐6‐phosphate dehydrogenase, others propose it acts instead as an F420‐dependent ...
Adewale V. Aderemi, Matthew Snee, Richard B. Tunnicliffe, Linus O. Johanissen, Matthew J. Cliff, Colin W. Levy, Derren J. Heyes, Marina Golovanova, Thomas A. Jowitt, Sam Hay, Andrew W. Munro, Jonathan P. Waltho, David Leys   +12 more
wiley   +1 more source

Preparation and evaluation of magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery

Journal of Acute Disease, 2013
Objective: To study magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery. Methods: Magnetic microspheres were prepared by solvent evaporation technique for use in the application of magnetic carrier technology.
Satinder Kakar, Deepa Batra, Ramandeep Singh   +2 more
doaj   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source

Sulfated Cyclocarya Paliurus Polysaccharide Sorchestrates the Gut Microbiome to Mobilize a Host‐Derived 12‐HEPE Against Ulcerative Colitis

Advanced Science, Volume 13, Issue 44, 7 August 2026.
A sulfated polysaccharide (SCP) from Cyclocarya paliurus alleviates ulcerative colitis by reshaping the gut microbiome. This remodeled microbiota orchestrates the upregulation of the host‐derived lipid 12‐HEPE, which directly inhibits the TLR4/NF‐κB pathway to suppress inflammation.
Xianxiang Chen, Mingyue Shen, Rui Zhang, Zhibing Huang, Hui Niu, Qiang Yu, Yi Chen, Xiangwen Pan, Liyuan Rong, Huiliang Wen, Jun Yang, Jianhua Xie   +11 more
wiley   +1 more source

Risk factors for adverse events in patients with multidrug-resistant tuberculosis, HIV-infection and viral hepatitis C

Терапевтический архив
Aim. To identify risk factors for adverse drug reactions (ADRs) in patients co-infected with multidrug-resistant tuberculosis (MDR-TB), HIV and viral hepatitis C (HCV). Materials and methods.
Anastasiia V. Kukurika
doaj   +1 more source